Immunization of rhesus monkeys with high- and low-dose Tween-ether-disrupted SIVMAC.
Two vaccine trials were conducted with low- and high-dose purified Twen-ether-treated SIVmac adsorbed onto aluminum hydroxide using rhesus macaques. In the first experiment 7 macaques were immunized with a total amount of 560 micrograms protein and 3 animals served as controls. After the immunization period the vaccinees exhibited ELISA titers up to 1:1280 and 5 immunized animals showed an antigen-specific proliferative response. After the virus challenge the 3 control animals and 3 vaccinees became infected. Four of the infected animals developed a cytotoxic T-cell response beginning 8 weeks postchallenge. The 4 protected animals were rechallenged 16 weeks later and all became infected. For the high-dose experiment 5 immunized animals receiving 2 mg of antigen and 2 control animals were used. The ELISA titers of the vaccinees reached 1:20480 and 4 animals exhibited an antigen-specific proliferative response. In response to virus challenge the 2 control and 1 immunized animal became infected. From these data it can be concluded that the high-dose immunization scheme elicited higher antibody titers and increased the fraction of protected animals.
Voss
G
G
Deutsches Primatenzentrum, Abteilung Virologie und Immunologie, Göttingen, Germany.
Stahl-Hennig
C
C
Petry
H
H
Coulibaly
C
C
Nick
S
S
Fuchs
D
D
Wachter
H
H
Lüke
W
W
Hunsmann
G
G
D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000956:Antigens, Viral / Q000008:administration & dosage / Q000276:immunology*; D001708:Biopterins / Q000031:analogs & derivatives / Q000032:analysis; D004306:Dose-Response Relationship, Immunologic; D004986:Ether; D008253:Macaca mulatta / Q000276:immunology*; D019798:Neopterin; D011136:Polysorbates; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000956:Antigens, Viral; D011136:Polysorbates; D015164:Vaccines, Inactivated; D014765:Viral Vaccines; D004986:Ether; D001708:Biopterins; D000536:Aluminum Hydroxide; D019798:Neopterin